Rep. Josh Gottheimer Sells Genmab A/S (NASDAQ:GMAB) Stock

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Genmab A/S NASDAQ: GMAB. In a filing disclosed on January 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Genmab A/S stock on December 16th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Block NYSE: SQ on 12/30/2024.
• Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 12/30/2024.
• Sold $1,001 - $15,000 in shares of Ambev NYSE: ABEV on 12/27/2024.
• Sold $1,001 - $15,000 in shares of Grupo Financiero Banorte OTCMKTS: GBOOY on 12/27/2024.
• Sold $1,001 - $15,000 in shares of Cadre NYSE: CDRE on 12/27/2024.
• Sold $1,001 - $15,000 in shares of Coloplast A/S OTCMKTS: CLPBY on 12/27/2024.
• Sold $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 12/23/2024.
• Sold $1,001 - $15,000 in shares of Trane Technologies NYSE: TT on 12/23/2024.
• Purchased $1,001 - $15,000 in shares of Walmart NYSE: WMT on 12/20/2024.
• Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 12/19/2024.

Genmab A/S Trading Up 4.9 %

GMAB traded up $0.99 during trading on Thursday, hitting $21.22. 2,663,041 shares of the company's stock were exchanged, compared to its average volume of 1,169,450. Genmab A/S has a 1 year low of $19.85 and a 1 year high of $31.88. The stock has a 50 day moving average price of $21.23 and a 200 day moving average price of $24.12. The firm has a market cap of $14.04 billion, a P/E ratio of 20.60, a price-to-earnings-growth ratio of 0.59 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million for the quarter, compared to analysts' expectations of $838.20 million. During the same period last year, the company posted $0.47 earnings per share. Analysts forecast that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GMAB has been the topic of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a report on Wednesday, January 8th. BMO Capital Markets reiterated an "outperform" rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Finally, Redburn Atlantic began coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a "buy" rating for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $45.20.

Institutional Trading of Genmab A/S

A number of hedge funds have recently made changes to their positions in the stock. Two Sigma Advisers LP raised its holdings in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after acquiring an additional 280,900 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock valued at $7,000,000 after purchasing an additional 145,689 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after purchasing an additional 103,859 shares during the period. Sanctuary Advisors LLC bought a new position in shares of Genmab A/S in the 2nd quarter worth about $1,354,000. Finally, Natixis Advisors LLC boosted its holdings in shares of Genmab A/S by 29.8% in the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock valued at $5,036,000 after buying an additional 47,437 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2025. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2024 election. Gottheimer was first elected to the House in 2016. Prior to his election, Gottheimer worked for Microsoft, the Federal Communications Commission, and for the administration of President Bill Clinton (D). Click here for more information about Gottheimer's career. Gottheimer serves on the House Financial Services Committee, where is a member of three subcommittees. For more on Gottheimer's committee assignments, click here. Gottheimer became a co-chair of the Problem Solvers Caucus in February 2017. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.